Compare Emerson Electric Co. (EMR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Novo Nordisk A/S — how do they compare? Emerson Electric Co. trades at $162.23 (market cap $88.72B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Novo Nordisk A/S for 116 Days on average.
| EMR | NVO | |
|---|---|---|
Market Cap | $88.72B | $165.31B |
Volume | 2,355,255 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $164.38 | $63.98 |
52-Week Low | $123.30 | $35.29 |
Typical Hold Time | 81 Days | 116 Days |
Enterprise Value | $99.80B | $179.56B |
Dividend Yield | 1.4% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.83, up 1.64% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 13.83% net income margin and a 12.81% ROE. Revenue is projected to grow to $18.6B in 2026, and the company maintains a solid balance sheet with $3.59B in cash. Analysts are largely positive, with a consensus price target of $165.90.
EMR presents a favorable outlook with upward earnings momentum and analyst support, though valuation multiples like a P/E of 34.81 suggest premium pricing. Risks include competitive pressures and macroeconomic volatility. The stock remains a candidate for growth-oriented investors seeking industrial sector exposure.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
